Assessing response of therapy for acute and chronic graft-versus-host disease

Expert Review of Hematology

Volumn 6, Issue 1, 2013, Pages 103-107

  Goldberg, Jenna D ^a   Giralt, Sergio ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

allogeneic transplant; biomarkers; GVHD; response assessment

Indexed keywords

B CELL ACTIVATING FACTOR; BIOLOGICAL MARKER; ELAFIN; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 8; SCATTER FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL (TOPIC); HUMAN; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; REGULATORY T LYMPHOCYTE; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACUTE DISEASE; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84873348274     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.12.65     Document Type: Review

References (25)

1. Weisdorf D, Haake R, Blazar B et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: An analysis of clinical risk features and outcome. Blood 75(4), 1024-1030 (1990). (Pubitemid 20067206)
2. Gómez-Almaguer D, Ruiz-Argüelles GJ, del Carmen Tarín-Arzaga L et al. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biol. Blood Marrow Transplant. 14(1), 10-15 (2008). (Pubitemid 350286746)
3. Lee SJ, Kim HT, Ho VT et al. Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant. 38(4), 305-310 (2006). (Pubitemid 44203780)
4. Rowlings PA, Przepiorka D, Klein JP et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br. J. Haematol. 97(4), 855-864 (1997). (Pubitemid 27321388)
5. Filipovich AH, Weisdorf D, Pavletic S et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol. Blood Marrow Transplant. 11(12), 945-956 (2005). (Pubitemid 41754712)
6. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N. Engl. J. Med. 314(12), 729-735 (1986). (Pubitemid 16124386)
7. Martin PJ, Schoch G, Fisher L et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 76(8), 1464-1472 (1990). (Pubitemid 20364008)
8. Mielcarek M, Storer BE, Boeckh M et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood 113(13), 2888-2894 (2009).
9. Lee SJ. Have we made progress in the management of chronic graft-vs-host disease? Best Pract. Res. Clin. Haematol. 23(4), 529-535 (2010).
10. MacMillan ML, DeFor TE, Weisdorf DJ. The best endpoint for acute GVHD treatment trials. Blood 115(26), 5412-5417 (2010).
11. Levine JE, Logan B, Wu J et al.; Blood and Marrow Transplant Clinical Trials Network. Graft-versus-host disease treatment: predictors of survival. Biol. Blood Marrow Transplant. 16(12), 1693-1699 (2010).
12. Saliba RM, Couriel DR, Giralt S et al. Prognostic value of response after upfront therapy for acute GVHD. Bone Marrow Transplant. 47(1), 125-131 (2012).
13. Pavletic SZ, Martin P, Lee SJ et al.; Response Criteria Working Group. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol. Blood Marrow Transplant. 12(3), 252-266 (2006). (Pubitemid 43273710)
14. Levine JE, Logan BR, Wu J et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: A Blood and Marrow Transplant Clinical Trials Network study. Blood 119(16), 3854-3860 (2012).
15. MacMillan ML, Weisdorf DJ, Wagner JE et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol. Blood Marrow Transplant. 8(7), 387-394 (2002).
16. Alousi AM, Weisdorf DJ, Logan BR et al.; Blood and Marrow Transplant Clinical Trials Network. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: A randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 114(3), 511-517 (2009).
17. Martin PJ, Nash RA. Pitfalls in the design of clinical trials for prevention or treatment of acute graft-versus-host disease. Biol. Blood Marrow Transplant. 12(1 Suppl. 2), 31-36 (2006). (Pubitemid 43034109)
18. Martin PJ, McDonald GB, Sanders JE et al. Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 10(5), 320-327 (2004). (Pubitemid 38519570)
19. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75(3), 555-562 (1990). (Pubitemid 20069191)
20. Chronic GVHD Consortium. Rationale and design of the chronic GVHD cohort study: improving outcomes assessment in chronic GVHD. Biol. Blood. Marrow Transplant. 17(8), 1114-1120 (2011).
21. Arai S, Jagasia M, Storer B et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood 118(15), 4242-4249 (2011).
22. Paczesny S, Krijanovski OI, Braun TM et al. A biomarker panel for acute graft-versus-host disease. Blood 113(2), 273-278 (2009).
23. Paczesny S, Braun TM, Levine JE et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci. Transl. Med. 2(13), 13ra2 (2010).
24. Ferrara JL, Harris AC, Greenson JK et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versushost disease. Blood 118(25), 6702-6708 (2011).
25. Schultz KR, Miklos DB, Fowler D et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol. Blood Marrow Transplant. 12(2), 126-137 (2006). (Pubitemid 43138008)